Kowa Company, Ltd.

Privately held: no public share price

Assets

(3 total)
3Total Assets
0Approved
2Phase 3 / Filed
1Phase 1–2 / Early
5Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Anagliptin(Suiny)
Phase 3
DPP-4Small molecule
Type 2 Diabetes
Pemafibrate(Parmodia)
Phase 3
PPAR-alphaSmall molecule
Atherosclerotic Cardiovascular DiseaseSevere HypertriglyceridemiaCardiovascular Disease / DyslipidemiaCholestatic Liver Disease
Hypertriglyceridemia, Primary Biliary Cholangitis
Tofogliflozin(Apleway / Deberza)
Phase 2
SGLT2Small molecule
Type 2 Diabetes

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.